Fas promoter polymorphisms: genetic predisposition to sarcoidosis in African-Americans.

Apoptosis may perpetuate some forms of inflammation. Of the apoptotic pathway proteins, Fas is particularly overexpressed in sarcoidosis. We hypothesized that Fas promoter single nucleotide polymorphisms (SNPs) contribute to the development and severity of sarcoidosis. Associations of known Fas promoter SNPs (-670, -690 and -1377) and deduced haplotypes with sarcoidosis and sarcoidosis severity were evaluated using matched case-control (n = 656 pairs) and case-comparison (n = 656) studies, respectively, using conditional logistic regression. Hardy-Weinberg equilibrium was confirmed for all three polymorphisms in African-Americans (AA), and for the -670 and -1377 in whites. Genotype and allele frequencies were significantly different between whites and AA. Race-stratified analysis revealed that a common haplotype, -1377G/-690T/-670G, was associated with sarcoidosis [odds ratio (OR) = 1.78, P = 0.05] only in AA. The haplotype -1377G/-690C/-670A was negatively associated with sarcoidosis (OR = 0.39, P = 0.03) only in AA. In conclusion, the consistency of these findings suggests that Fas promoter genetic variants may be related to sarcoidosis disease risk in AA.

[1]  L. Chouchane,et al.  A polymorphism in FAS gene promoter correlated with circulating soluble FAS levels , 2007, International journal of immunogenetics.

[2]  F. Pociot,et al.  Functional promoter haplotypes of the human FAS gene are associated with the phenotype of SLE characterized by thrombocytopenia , 2005, Genes and Immunity.

[3]  P. Spagnolo,et al.  C-C chemokine receptor 5 gene variants in relation to lung disease in sarcoidosis. , 2005, American journal of respiratory and critical care medicine.

[4]  R. Elston,et al.  Genome-wide search for sarcoidosis susceptibility genes in African Americans , 2005, Genes and Immunity.

[5]  P. Spagnolo,et al.  C-C chemokine receptor 2 and sarcoidosis: association with Lofgren's syndrome. , 2003, American Journal of Respiratory and Critical Care Medicine.

[6]  M. Iannuzzi,et al.  HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. , 2003, American journal of human genetics.

[7]  T. Ahmad,et al.  HLA-DQB1*0201: a marker for good prognosis in British and Dutch patients with sarcoidosis. , 2002, American journal of respiratory cell and molecular biology.

[8]  F. Barkhof,et al.  The FAS−670 polymorphism influences susceptibility to multiple sclerosis , 2002, Journal of Neuroimmunology.

[9]  V. Fadok,et al.  Beryllium induces apoptosis in human lung macrophages. , 2002, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[10]  G. McLennan,et al.  Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). , 2001, American journal of respiratory and critical care medicine.

[11]  G. McLennan,et al.  Clinical characteristics of patients in a case control study of sarcoidosis. , 2001, American journal of respiratory and critical care medicine.

[12]  B. Müller-Myhsok,et al.  Results from a genome-wide search for predisposing genes in sarcoidosis. , 2001, American journal of respiratory and critical care medicine.

[13]  V. Fadok,et al.  Beryllium-stimulated apoptosis in macrophage cell lines. , 2000, Toxicology.

[14]  F. Pociot,et al.  Complete molecular scanning of the human Fas gene: mutational analysis and linkage studies in families with Type I diabetes mellitus , 2000, Diabetologia.

[15]  L. Newman,et al.  Beryllium-stimulated production of tumor necrosis factor-alpha by a mouse hybrid macrophage cell line. , 2000, Toxicology.

[16]  R. Baughman.  Design of a case control etiologic study of sarcoidosis (ACCESS). ACCESS Research Group. , 1999, Journal of clinical epidemiology.

[17]  R. Baughman,et al.  Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. , 1999, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[18]  M. Iannuzzi.  Genetics of sarcoidosis. , 1998, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[19]  J. Grunewald,et al.  HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. , 1997, American journal of respiratory and critical care medicine.

[20]  N. Manolios,et al.  Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. , 1997, Molecular immunology.

[21]  R. Zambello,et al.  Expression of tumor necrosis factor-receptor superfamily members by lung T lymphocytes in interstitial lung disease. , 1996, American journal of respiratory and critical care medicine.

[22]  兼光 聡美.  A functional polymorphism in Fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus , 2003 .

[23]  國武 律子.  Apoptosis in the course of granulomatous inflammation in pulmonary sarcoidosis , 2001 .

[24]  P. Droszcz,et al.  Expression of Fas antigen in the cells from bronchoalveolar lavage fluid (BALF). , 2000, Folia histochemica et cytobiologica.

[25]  N. Manolios,et al.  INVESTIGATION OF THE -1377 POLYMORPHISM ON THE APO-1/FAS PROMOTER IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS USING ALLELE-SPECIFIC AMPLIFICATION , 2000, Pathology.

[26]  M. Bunce,et al.  Molecular typing for the MHC with PCR-SSP. , 1999, Reviews in immunogenetics.

[27]  H. Dai,et al.  Increased expression of apoptosis signalling receptors by alveolar macrophages in sarcoidosis. , 1999, The European respiratory journal.